IL322257A - שיטות לטיפול בסרטן השד - Google Patents

שיטות לטיפול בסרטן השד

Info

Publication number
IL322257A
IL322257A IL322257A IL32225725A IL322257A IL 322257 A IL322257 A IL 322257A IL 322257 A IL322257 A IL 322257A IL 32225725 A IL32225725 A IL 32225725A IL 322257 A IL322257 A IL 322257A
Authority
IL
Israel
Prior art keywords
dose
neob
administered
treatment
ribociclib
Prior art date
Application number
IL322257A
Other languages
English (en)
Inventor
Paola Daniela Aimone
Lars Blumenstein
Silvia Cacciatore
Azzeddine Cherfi
Dhrubajyoti Pathak
Kevin Perraud
Original Assignee
Novartis Ag
Paola Daniela Aimone
Lars Blumenstein
Silvia Cacciatore
Azzeddine Cherfi
Dhrubajyoti Pathak
Kevin Perraud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Paola Daniela Aimone, Lars Blumenstein, Silvia Cacciatore, Azzeddine Cherfi, Dhrubajyoti Pathak, Kevin Perraud filed Critical Novartis Ag
Publication of IL322257A publication Critical patent/IL322257A/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL322257A 2023-02-23 2024-02-21 שיטות לטיפול בסרטן השד IL322257A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363486496P 2023-02-23 2023-02-23
US202463625371P 2024-01-26 2024-01-26
PCT/IB2024/051682 WO2024176147A1 (en) 2023-02-23 2024-02-21 Methods for treating breast cancer

Publications (1)

Publication Number Publication Date
IL322257A true IL322257A (he) 2025-09-01

Family

ID=90059256

Family Applications (1)

Application Number Title Priority Date Filing Date
IL322257A IL322257A (he) 2023-02-23 2024-02-21 שיטות לטיפול בסרטן השד

Country Status (9)

Country Link
EP (1) EP4669363A1 (he)
JP (1) JP2026506981A (he)
KR (1) KR20250149794A (he)
CN (1) CN121013734A (he)
AU (1) AU2024225706A1 (he)
IL (1) IL322257A (he)
MX (1) MX2025009867A (he)
TW (1) TW202434313A (he)
WO (1) WO2024176147A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025126151A1 (en) * 2023-12-15 2025-06-19 Novartis Ag Methods for treating breast cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114728088A (zh) 2019-09-16 2022-07-08 诺华股份有限公司 稳定的浓缩的放射性药物组合物
TWI878344B (zh) 2019-09-17 2025-04-01 瑞士商諾華公司 放射性標記grpr拮抗劑之方法及其套組
WO2021171261A1 (en) 2020-02-28 2021-09-02 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor

Also Published As

Publication number Publication date
KR20250149794A (ko) 2025-10-16
JP2026506981A (ja) 2026-02-27
CN121013734A (zh) 2025-11-25
TW202434313A (zh) 2024-09-01
MX2025009867A (es) 2025-09-02
EP4669363A1 (en) 2025-12-31
WO2024176147A1 (en) 2024-08-29
AU2024225706A1 (en) 2025-07-31

Similar Documents

Publication Publication Date Title
JP2025503451A (ja) 炭酸脱水酵素ixリガンド
TWI605815B (zh) 用於製備包含阿米福丁與胺基酸之腎保護劑的組成物及方法
IL322257A (he) שיטות לטיפול בסרטן השד
US9180214B1 (en) Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer
JP7665726B2 (ja) アルファ放射標識ガストリンアナログおよびcckb受容体陽性疾患の処置方法におけるその使用
IL322112A (he) שיטות לטיפול בגליובלסטומה
JP7665727B2 (ja) 特にcckb受容体陽性の癌もしくは腫瘍の処置および/または診断に使用するための、ラパログと放射標識ガストリンアナログとを含む組成物
IL303930A (he) אנטגוניסט רדיואקטיבי לאלפא v בטא 3 ו\או אלפא v בטא 4 אינטגרינים ושימוש שלהם בתור חומר תראגוניסטי
WO2025126151A1 (en) Methods for treating breast cancer
JP2023536261A (ja) Cckb受容体陽性腫瘍または癌の画像化方法におけるガリウム標識ガストリン類似体および使用
CA3234495A1 (en) Combination therapy of radionuclide complex
Facca EGFR and HER2-targeted radioimmunoconjugates for theranostic molecular imaging and Auger electron radioimmunotherapy of breast cancer
KR20260014588A (ko) 전립선암의 진단 및/또는 치료 방법
WO2026088112A1 (en) Combination therapies with ar-degrading agents and psma-targeting radioligands
KR20250109190A (ko) 암의 식별 및/또는 치료
JP2005535676A5 (he)
JP2005535676A (ja) 腫瘍の処置における放射免疫療法の効果の増強